ATE406371T1 - Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung - Google Patents
Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendungInfo
- Publication number
- ATE406371T1 ATE406371T1 AT01989211T AT01989211T ATE406371T1 AT E406371 T1 ATE406371 T1 AT E406371T1 AT 01989211 T AT01989211 T AT 01989211T AT 01989211 T AT01989211 T AT 01989211T AT E406371 T1 ATE406371 T1 AT E406371T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- decrease
- infection
- treatment
- active ingredients
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24532900P | 2000-11-02 | 2000-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE406371T1 true ATE406371T1 (de) | 2008-09-15 |
Family
ID=22926225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01989211T ATE406371T1 (de) | 2000-11-02 | 2001-11-02 | Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung |
Country Status (7)
Country | Link |
---|---|
US (5) | US7153882B2 (de) |
EP (1) | EP1349858B1 (de) |
AT (1) | ATE406371T1 (de) |
AU (2) | AU4332302A (de) |
CA (1) | CA2465534C (de) |
DE (1) | DE60135579D1 (de) |
WO (1) | WO2002048150A2 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE406371T1 (de) * | 2000-11-02 | 2008-09-15 | Us Gov Health & Human Serv | Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung |
US20040024043A1 (en) * | 2002-03-22 | 2004-02-05 | Nigel Greig | Method for treating cognitive disorders |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
CA2514184C (en) | 2003-01-21 | 2016-04-12 | Ptc Therapeutics, Inc. | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same |
US8426194B2 (en) | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
ATE464048T1 (de) * | 2003-08-07 | 2010-04-15 | Merck Sharp & Dohme | Behandlung von alzheimer-krankheit und verwandten zuständen |
US20070072186A1 (en) * | 2003-11-17 | 2007-03-29 | Anuradha Mehta | Methods and agents for screening for compounds capable of modulating her2 expression |
US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
GB0410238D0 (en) | 2004-05-07 | 2004-06-09 | Merck Sharp & Dohme | Therapeutic agents |
EP1604686A1 (de) * | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Verwendung von Phenserine und einem HMG CoA reduktase Hemmer zur Verzögerung der Alzheimer Krankheit |
WO2006060082A1 (en) * | 2004-10-22 | 2006-06-08 | THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH | Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors |
US20060105940A1 (en) * | 2004-11-03 | 2006-05-18 | Axonyx, Inc. | Compound useful in the treatment or prevention of cognitive disorders associated with diabetes and associated methods |
CA2587487A1 (en) * | 2004-11-12 | 2006-05-18 | Pfizer, Inc. | Method of measuring amyloid-beta peptides |
US9095573B2 (en) * | 2005-08-01 | 2015-08-04 | University Of Central Florida Research Foundation, Inc. | Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble βAPP in tissue or CSF |
US8283115B1 (en) | 2007-06-20 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation |
US8283116B1 (en) | 2007-06-22 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation |
WO2010090009A1 (ja) * | 2009-02-05 | 2010-08-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | インドリン誘導体 |
US20100317731A1 (en) * | 2009-06-12 | 2010-12-16 | Shaya Elias K | Hyperhidrosis treatment |
WO2012058031A2 (en) * | 2010-10-28 | 2012-05-03 | Qr Pharma, Inc. | Novel method for preparation of bisnorcymerine and salts thereof |
US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
US10111860B1 (en) | 2016-01-15 | 2018-10-30 | Aristea Translational Medicine Corporation | Compositions and methods for treating concussion |
US10864192B2 (en) | 2016-01-15 | 2020-12-15 | Aristea Translational Medicine Corporation | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions |
WO2017214197A1 (en) | 2016-06-06 | 2017-12-14 | University Of Central Florida Research Foundation, Inc. | Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions |
CA3083015A1 (en) | 2017-05-24 | 2018-11-28 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
WO2022125616A1 (en) * | 2020-12-09 | 2022-06-16 | Caamtech, Inc. | Dialkyl trytamines and their therapeutic uses |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2890223A (en) * | 1956-03-22 | 1959-06-09 | Research Corp | 1-benzyl, 2-methyl, 5-methoxy tryptamine |
US4791107A (en) * | 1986-07-16 | 1988-12-13 | Hoechst-Roussel Pharmaceuticals, Inc. | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use |
US4900748A (en) * | 1988-03-04 | 1990-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Carbamates related to (-)-physostigmine as cholinergic agents |
US5260452A (en) * | 1989-11-03 | 1993-11-09 | Hoechst-Roussel Pharmaceuticals Inc. | 4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof |
FR2674522B1 (fr) | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
US5171750A (en) * | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
WO1993005779A1 (en) * | 1991-09-26 | 1993-04-01 | The United States Of America Represented By The Secretary Department Of Health And Human Services | Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases |
FR2707639B1 (fr) | 1993-06-30 | 1995-10-13 | Pf Medicament | Nouveaux composés indoliques dérivés d'arylamines comme ligands sélectifs des récepteurs 5HT1D et 5HT1B. |
JPH07271066A (ja) | 1994-03-29 | 1995-10-20 | Mitsubishi Paper Mills Ltd | 電子写真感光体 |
US5403851A (en) * | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
CA2196046A1 (en) | 1994-07-27 | 1996-02-08 | Nigel Birdsall | Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors |
CZ297533B6 (cs) * | 1997-07-09 | 2007-01-03 | Axonyx | Použití inhibitorů butyrylcholinesterázy pro léčbu a diagnostiku Alzheimerovy choroby a demence |
NZ506329A (en) | 1998-02-25 | 2004-01-30 | Inst Genetics Llc | Inhibitors of phospholipase enzymes |
US20010007877A1 (en) * | 1998-12-16 | 2001-07-12 | George O. Burton | Novel anti-infectives |
US20020004198A1 (en) * | 1998-12-16 | 2002-01-10 | Hardwicke Mary Ann | Novel anti-infectives |
GB9918962D0 (en) * | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxii |
WO2001034146A1 (en) | 1999-11-08 | 2001-05-17 | Smithkline Beecham Corporation | Novel anti-infectives |
AU5702201A (en) | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
ATE406371T1 (de) * | 2000-11-02 | 2008-09-15 | Us Gov Health & Human Serv | Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung |
-
2001
- 2001-11-02 AT AT01989211T patent/ATE406371T1/de active
- 2001-11-02 DE DE60135579T patent/DE60135579D1/de not_active Expired - Lifetime
- 2001-11-02 WO PCT/US2001/048175 patent/WO2002048150A2/en active IP Right Grant
- 2001-11-02 CA CA002465534A patent/CA2465534C/en not_active Expired - Lifetime
- 2001-11-02 AU AU4332302A patent/AU4332302A/xx active Pending
- 2001-11-02 EP EP01989211A patent/EP1349858B1/de not_active Expired - Lifetime
- 2001-11-02 US US10/415,765 patent/US7153882B2/en not_active Expired - Lifetime
- 2001-11-02 AU AU2002243323A patent/AU2002243323B2/en not_active Expired
-
2006
- 2006-06-20 US US11/455,959 patent/US20060270729A1/en not_active Abandoned
-
2009
- 2009-01-21 US US12/357,115 patent/US7786162B2/en active Active
-
2010
- 2010-07-22 US US12/841,888 patent/US8258172B2/en active Active
-
2012
- 2012-07-26 US US13/559,186 patent/US8691864B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20060270729A1 (en) | 2006-11-30 |
AU2002243323B8 (en) | 2002-06-24 |
DE60135579D1 (de) | 2008-10-09 |
US8258172B2 (en) | 2012-09-04 |
WO2002048150A3 (en) | 2003-08-07 |
US20090131501A1 (en) | 2009-05-21 |
AU2002243323B2 (en) | 2007-07-12 |
US7786162B2 (en) | 2010-08-31 |
US20120295946A1 (en) | 2012-11-22 |
AU4332302A (en) | 2002-06-24 |
US7153882B2 (en) | 2006-12-26 |
US20040138282A1 (en) | 2004-07-15 |
EP1349858A2 (de) | 2003-10-08 |
US8691864B2 (en) | 2014-04-08 |
EP1349858B1 (de) | 2008-08-27 |
CA2465534C (en) | 2009-10-27 |
CA2465534A1 (en) | 2002-06-20 |
US20110021594A1 (en) | 2011-01-27 |
WO2002048150A2 (en) | 2002-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE406371T1 (de) | Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung | |
EA200400482A1 (ru) | Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран | |
ATE202701T1 (de) | Behandlung und prophylaxe von durch parasiten oder bakterien verursachten erkrankungen | |
DE60207383D1 (de) | Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen | |
DE60312031D1 (de) | Hydroxyethylamin-derivate für die behandlung von alzheimer | |
DE60319066D1 (de) | 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DE69909818D1 (de) | Pyrazolopyimidinon-derivate zur behandlung von impotenz | |
ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
DE60026152D1 (de) | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs | |
ATE147981T1 (de) | Verabreichung von lamotrigin zur behandlung von neuro-aids | |
DE602004017481D1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
DE60210614D1 (de) | Für die behandlung von alzheimer krankheit geeignete makrocyclen | |
ATE330943T1 (de) | Herstellungsverfahren von huperzine a und deren analogen und verbindungen nützlich dazu | |
EA200301040A1 (ru) | Способ производства фармацевтической композиции низкой дозы | |
DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
DE60217356D1 (de) | Creme zur behandlung von sonnengeschädigter haut | |
DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
ATE40946T1 (de) | Arzneimittel oder prophylaktisches mittel zur behandlung von epilepsie. | |
ATE205399T1 (de) | Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält | |
ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
DE50008908D1 (de) | Verwendung einer pharmazeutischen zusammensetzung zur herstellung eines medikamentes zur behandlung von durch bakterien, viren, pilze, hefen und/oder protozoen verursachten augenerkrankungen | |
ATE359995T1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1349858 Country of ref document: EP |